Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Aethlon Medical partners Sarcoma to implement cancer studies

Aethlon Medical : 25 August, 2011  (Company News)
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, enters into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

Exosomes released by cancer have recently emerged as a novel therapeutic target in cancer care, as they have been implicated in cancer survival, growth, and metastasis.  Researchers have also identified that cancer-released exosomes may assist tumours in evading the response of the immune system.  At present, there is no therapeutic drug candidate to inhibit the deleterious roles of cancer-released exosomes.  The Aethlon Hemopurifier is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including HIV and Hepatitis C virus.  The device has also demonstrated the ability to capture cancer-released exosomes from cell culture and human ascites fluids. 


"The opportunity to test the ability of our Hemopurifier to remove exosomes from the blood of cancer patients represents an important step in our effort to improve cancer care," said Aethlon Chairman and Chief Executive Officer, Jim Joyce.  "Additionally, we will have the privilege of working with Dr Sant Chawla, a leading authority in the sarcoma oncology field and his team at the Sarcoma Oncology Center."

 

The study will be conducted in collaboration with The Sarcoma Oncology Center based in Santa Monica, California.  The Sarcoma Oncology Center is one of the most sought after research centres for the clinical testing of new therapeutic candidates against sarcomas and other forms of cancer.  


The lead investigator of the study is Dr Chawla, noted: "This clinical histological study is a critical validation step in Aethlon's Hemopurifier strategy for cancer that we hope will set the stage for planned therapeutic trials in cancer patients. The concept of 'subtractive therapy', eliminating a major mechanism of tumour progre ssion and resistance to drugs, represents a potential breakout solution that needs to be tested in the clinic." 


The initial study will quantitate and capture exosomes ex-vivo, from blood samples of patients with advanced cancers. The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. 


Successful study outcomes would provide a basis for advancing human studies of the Aethlon Hemopurifier as an adjunct therapy to improve patient responsiveness to established cancer therapies.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo